{"prompt": "['Trelagliptin-4002', 'Page 12 of 66', 'Version 1.0', 'November 2, 2016', '3.', 'Patients with severe renal impairment or renal failure (e.g., eGFR <30 mL/min/1.73 m\u00b2 or on', 'dialysis).', '4.', 'Patients with serious heart disease or cerebrovascular disorder, or serious pancreatic, blood, or', 'other disease.', '5.', 'Patients with a history of gastrointestinal resection.', '6.', 'Patient with a proliferative diabetic retinopathy.', '7.', 'Patient with malignancy.', '8.', 'Patients with a history of hypersensitivity or allergy to DPP-4 inhibitors.', '9.', 'Pregnant, lactating or postmenopausal women.', '10. Patients who may need to add or discontinue concomitant medication or change the dose during', 'the study period.', '11. Patients who will require treatment with a prohibited concomitant medication during the study', 'period.', '12. Patients participating in other clinical studies.', '13. Patients assessed ineligible in the study by the principal investigator or the investigator.', 'ENDPOINTS:', '<Primary endpoint>', 'Change from baseline (Week 0) in total score for all question items in the DTR-QOL Questionnaire', 'at the end of the treatment period (Week 12).', '<Secondary endpoints>', 'Efficacy assessment:', 'Changes in the total score for each factor provided through the DTR-QOL Questionnaire', '[Factor 1: Burden on social activities and daily activities (13 questions in all), Factor 2: Anxiety', 'and dissatisfaction with treatment (8 questions in all), Factor 3: Hypoglycemia (4 questions in', 'all) and Factor 4: Treatment satisfaction (4 questions in all) at each assessment time point.', 'Change in the total score for all questions in the DTR-QOL Questionnaire at each assessment', 'time point.', 'Change in the total score for all questions in the Diabetes Treatment Satisfaction Questionnaire', '(DTSQ) at each assessment time point.', 'Changes in the total scores for all questions in the DTR-QOL Questionnaire and DTSQ,', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 13 of 66', 'Version 1.0', 'November 2, 2016', 'stratified by the following factors at the start of the treatment period (Week 0) within each', 'treatment group.', 'Use of medication for treatment of comorbidities', 'Number of daily doses, including medication for treatment of comorbidities (<2 times or', '>2 times)', 'Total number of daily tablets, including medication for treatment of comorbidities (<2', 'tablets or >2 tablets)', 'Number of doses of the study drug or comparative drug (once weekly, once daily or twice', 'daily)', 'Changes in the scores per question in the DTR-QOL Questionnaire at each assessment time', 'point.', 'Changes in the scores per question in the DTSQ at each assessment time point.', 'Safety assessment:', 'Adverse events', 'Incidence of hypoglycemia', 'Hospitalization for type 2 diabetes (duration and number, excluding educational hospitalization', 'without worsening of diabetes)', '<Other Endpoints>', 'Laboratory tests [HbA1c, fasting blood glucose, fasting insulin, fasting glucagon,', 'glycoalbumin, 1,5-AG, serum creatinine, urinary 8-OHdG (using a correction value of uric', 'creatinine (8-OHdG/creatinine)) and urinary creatinine]', 'Treatment compliance', 'The Basic Information on Study Subject (Your Basic Profile)', 'STATISTICAL ANALYSIS METHODS:', '<Analysis Sets>', 'Two analysis sets comprising the \"Full Analysis Set (FAS)\" and the \"Safety Population\" will be', 'established. The FAS used as the main efficacy analysis set is defined as \"randomized subjects who', 'receive at least one dose of trelagliptin or daily DPP-4 inhibitor.\" The safety population is defined', 'as \"subjects who receive at least 1 dose of trelagliptin or daily DPP-4 inhibitor.\"', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 14 of 66', 'Version 1.0', 'November 2, 2016', '<Primary endpoint>', 'Change from baseline (Week 0) in total score for all question items in the DTR-QOL', 'Questionnaire at the end of the treatment period (Week 12).', '(1) A comparison between the treatment groups will be carried out based on the ANCOVA', 'model using a change in the total score by the end of treatment [the end of the treatment', 'period (Week 12) - baseline (Week 0)] as a dependent variable; the total score at the', 'baseline (Week 0), the total score of the DTR-QOL Questionnaire (<80% or 80%) at the', 'start of the screening period and HbAlc (<8.0% or 8.0%) at the start of the screening', 'period as covariates; and a treatment group as an independent variable. The level of', 'significance will be 5% (two-sided).', '<Secondary endpoints>', 'Efficacy endpoints:', 'Change in the total score for each factor provided through the DTR-QOL Questionnaire', '[\"Factor 1: Burden on social activities and daily activities (13 questions in all)\", \"Factor 2:', 'Anxiety and dissatisfaction with treatment (8 questions in all)\", \"Factor 3: Hypoglycemia (4', 'questions in all)\", and \"Factor 4: Treatment satisfaction (4 questions in all)\"] at each assessment', 'time point.', 'Change in the total score for all questions in the DTR-QOL Questionnaire at each assessment', 'time point.', 'Change in the total score for all questions in the DTSQ at each assessment time point.', '(1) Summary statistics [sample size, mean, standard deviation (SD), maximum, minimum and', 'quantile] and the two-sided 95% confidence interval (CI) for means per treatment group at', 'each assessment time point will be calculated to plot the changes in means and SDs. Point', 'estimates and the two-sided 95% CI for differences between the treatment groups will also', 'be calculated.', '(2) Changes from the baseline (Week 0) to each assessment time point will be calculated to be', 'similarly analyzed to 1) above.', '(3)', 'The analyses below carried out on the total score for each factor provided through the', 'DTR-QOL Questionnaire, and on the total score for DTSQ:', 'A comparison between the treatment groups will be carried out based on the ANCOVA', 'model using a change in the total score by the end of treatment [the end of the treatment', 'period (Week 12) - baseline (Week 0)] as a dependent variable; the total score at the', 'baseline (Week 0), the total score of \"the DTR-QOL Questionnaire (<80% or 80%)\"', 'at', 'the baseline (Week 0) and \"HbAlc (<8.0% or 8.0%)\" at the baseline (Week 0) as', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}